News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Laurent Pharmaceuticals Receives Approval From Health Canada to Commence Phase 2/3 Clinical Trial for Long COVID
Wednesday, August 30, 2023Laurent Pharmaceuticals Inc headquartered in Montreal has received approval from Health Canada to initiate the ESSOR trial a Phase randomized placebocontrolled study
Cantex Pharmaceuticals Initiates Investigator-initiated Phase 2 Clinical Trial to Study Azeliragon Combined with Stereotactic Radiosurgery for Brain Metastases Treatment
Tuesday, August 29, 2023Cantex Pharmaceuticals a clinicalstage pharmaceutical company focused on developing innovative therapies for cancer and lifethreatening conditions has announced the initiation of a Phase clinical trial
Sandoz Successfully Concludes Acquisition of Leading Antifungal Agent Mycamine® From Astellas, Further Strengthening Global Anti-infectives Portfolio
Monday, August 28, 2023Sandoz a major player in the field of generic and biosimilar medicines has successfully concluded the acquisition of the global brand rights for Mycamine micafungin sodium a leading systemic antifungal agent This acquisition was made from Astellas
Ceapro and Symrise Prolong Exclusive Global Supply and Distribution Agreement for Active Ingredients
Saturday, August 26, 2023Ceapro Inc publicly traded as CZO on TSXV and as CRPOF on OTCQX a burgeoning biotechnology enterprise specializing in the development and commercialization of active ingredients for the healthcare and cosmetic sectors has announced a significant amen...
Alentis Therapeutics Receives FDA Fast Track Designation for ALE.C04 in Treatment of Claudin-1 Positive HNSCC
Friday, August 25, 2023Alentis Therapeutics a clinicalstage biotechnology company has been granted Fast Track development status by the US Food and Drug Administration FDA for their drug candidate ALEC This drug is being developed to treat patients with recurrent or metast...
Maplight Therapeutics Has Announced the Successful Completion of the Second Phase 1 Clinical Trial for Their Novel Muscarinic Receptor Agonist, ML-007
Friday, August 25, 2023MapLight Therapeutics a clinicalstage biopharmaceutical company has successfully completed a second Phase clinical trial for its novel compound ML This compound is designed to target MM muscarinic receptor agonists with the aim of addressing brain
Techbio Pioneer Etcembly Introduces Industry's First Generative AI-crafted Bispecific T Cell Engager Exhibiting Picomolar Affinity
Thursday, August 24, 2023Etcembly a British techbio startup has emerged from stealth mode to reshape the landscape of immunotherapy Utilizing a pioneering pipeline of T cell receptor TCR therapeutics crafted through generative AI the company represents a remarkable stride fo...
Ventus Therapeutics Launches Phase 1 Clinical Trial for VENT-02: a New Orally Administered NLRP3 Inhibitor with Enhanced Brain Penetration
Wednesday, August 23, 2023Ventus Therapeutics has commenced a Phase clinical trial for VENT a groundbreaking oral NLRP inhibitor engineered to address neuroinflammatory diseases Marcelo Bigal MD PhD the CEO of the company expressed enthusiasm about reaching this pivotal junc...
Paradigm Therapeutics Acquires Advanced Late-stage "Breakthrough Therapy" for Treating All Subtypes of Epidermolysis Bullosa (EB)
Wednesday, August 23, 2023Paradigm Therapeutics Inc a prominent biopharmaceutical firm has successfully concluded the acquisition of the global rights to SD from Amicus Therapeutics SD represents a topical remedy designed to address all subtypes of Epidermolysis Bullosa EB
European Medicines Agency Approves Orphan Disease Application for Cellspan Esophageal Implant
Tuesday, August 22, 2023Harvard Apparatus Regenerative Technology Inc OTCQB HRGN a clinicalstage biotechnology firm specializing in organ regeneration to address severe diseases has disclosed the European Medicines Agencys EMA endorsement of an Orphan Disease Application fo...
